Biocompatible Hydrogel Patents: Leaders, Trends & White Space 2026
- Filing peaked in 2017 at 16 families and has not returned to that level since, with the 2022 midpoint sitting at 9 — a flat-to-declining trend rather than a growing one.
- One 1990s-era patent dominates citation counts US6129761A on injectable hydrogel compositions is cited over 1,030 times, far ahead of any other record in this corpus, meaning newer filings are still built against decades-old prior art.
- Filing is split across three IPC subclasses A61L (sterilising and disinfecting), A61K (medicinal preparations) and, well behind, A61P — so the densest claim pressure sits on formulation and delivery, not on structural scaffolding or genetic-engineering angles.
Filing growth compares 2021 (11 records) with 2024 (10) — a three-year span. 2024 is the most recent year we treat as complete: publication lags filing by roughly 18 months, so 2025 onwards are still filling in and any growth rate that ends there would understate the field. Top-5 share is the combined record count of the five largest assignees divided by all 119 records in scope (CR5), not by the ranked leaders only.
What this landscape covers
This landscape tracks patent families filed against injectable, tissue-engineering and scaffold hydrogels where the claims specifically address mechanical modulus, cell encapsulation, degradation rate, gelation kinetics, or bioactive functionalization. That combination narrows the field to formulations and processes engineered for a biological outcome, not general polymer chemistry. The IPC mix — concentrated in A61L and A61K with smaller pockets in C08F, C08L, C08J, A61F and C12N — shows the field is still mostly framed as a drug-delivery and sterilisation problem rather than a structural-implant or cell-therapy one.
Coverage runs from 2015 through the mid-2026 data cut-off. Because publication typically lags filing by around eighteen months, the last one to two years of any trend line will read lower than the true filing volume once those applications clear examination and publish.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
119 patent families make up this corpus, spread across major receiving offices and eight core IPC subclasses. The shape of both tells you where claim density already sits and where it has thinned out.
A 2017 peak that has not been repeated
Filings hit 16 families in 2017, the high point of the window tracked here. By the 2022 midpoint, annual volume had settled at 9, and it has not recovered — a pattern more consistent with a field consolidating around known formulations than one still expanding into new claim territory.
Two subclasses carry most of the weight
A61L (sterilising and disinfecting, 83 records) and A61K (medicinal preparations, 67) between them account for the bulk of filing activity. A61P (therapeutic activity, 15) and the polymer-chemistry classes C08F, C08L and C08J (10–12 each) trail well behind, and A61F (implants) and C12N (genetic engineering) sit at just 7 each — the thinnest-claimed corners of the map.
Shares are the percentage of the 119 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Biocompatible Hydrogels for Tissue Engineering with Eureka
This page is one run against one query. Ask Eureka your own question about biocompatible hydrogels for tissue engineering and every answer comes back with the patent numbers behind it.
Try EurekaThe prior art newer filings have to design around
Microfluidics device for fabrication of large, uniform, injectable hydrogel microparticles for cell encapsulation
A vertically oriented microfluidic device flows a hydrophilic polymer precursor solution into one inlet channel and a hydrophobic fluid into a second inlet channel; the two streams meet at a junction where the precursor disperses into uniform droplets destined to become cell-encapsulating hydrogel microparticles.Filed by Auburn University, published 2019-04-11.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | US6129761A | Injectable hydrogel compositions | 1,030 |
| 2 | US20060280797A1 | Blends of temperature sensitive and anionic polymers for drug delivery | 143 |
| 3 | US20100291191A1 | Tunable sustained release of a sparingly soluble hydrophobic therapeutic agent from a hydrogel matrix | 90 |
| 4 | WO1999015211A1 | Improved hydrogel for tissue engineering | 89 |
| 5 | US7767656B2 | Blends of temperature sensitive and anionic polymers for drug delivery | 83 |
| 6 | WO1996040304A1 | Injectable hydrogel compositions | 77 |
| 7 | WO2011002249A2 | In SITU forming hydrogel and biomedical use thereof | 54 |
| 8 | WO2009150651A1 | Injectable hydrogel forming chitosan mixtures | 34 |
| 9 | WO2021035217A1 | Compositions and methods for sustained drug release from an injectable hydrogel | 30 |
| 10 | US8815277B2 | In situ forming hydrogel and biomedical use thereof | 20 |
Citation counts inside a searched corpus skew toward older filings by construction — treat this as a map of foundational influence, not of what matters most today.
Each row carries its publication number; clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the numbers mean for a filing decision
Three patterns in this dataset matter more than the raw counts on their own.
One foundational patent still anchors the field
US6129761A on injectable hydrogel compositions carries more than seven times the citations of the next most-cited record. Anyone filing on injectable delivery mechanics should assume examiners will cite it, and should draft claims that visibly differentiate from its scope rather than build adjacent to it.
Filing has cooled since 2017
The peak of 16 families in 2017 has not been matched since, and the 2022 midpoint of 9 confirms the decline is not a one-year anomaly. Given the roughly 18-month publication lag, the last one to two years will revise upward, but the multi-year trajectory is still downward, not flat.
Claim pressure sits on formulation, not structure
A61L and A61K together account for well over half of all records, while structural-implant class A61F and gene-engineering class C12N sit at just 7 each. The field's claim density is concentrated on the chemistry of the gel and its delivery, leaving structural and genetic-engineering integration comparatively open.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to biocompatible hydrogels for tissue engineering, with the prior art for and against each one.
| Assignee | Co-assignee | Shared families |
|---|---|---|
| University of Porto | TU Ilmenau (Technische Universität Ilmenau) | 5 |
| REPROGENESIS INC | ZHOU TAO | 3 |
| REPROGENESIS INC | OMSTEAD DANIEL R | 3 |
| REPROGENESIS INC | NELSON GORDON P | 3 |
| REPROGENESIS INC | BORLAND KERMIT M | 3 |
| REPROGENESIS INC | ATALA ANTHONY | 2 |
| Asia University Industry-Academic Cooperation Foundation | PARK KYUNG MIN | 2 |
| Asia University Industry-Academic Cooperation Foundation | PARK KI DONG | 2 |
Only 10 co-assignee pairs appear across the full corpus, and the strongest is an academic pairing rather than an industry partnership — collaboration in this space is the exception, not the norm.
Who holds the claim space, and where it's thin
No assignee in this corpus filed in the most recent tracked year, which is consistent with the broader slowdown rather than any single company exiting the field. That makes the sub-areas below more about structural opportunity than about displacing an active incumbent.
University of Pittsburgh's Federal system
Appears among the named assignees in this corpus but shows no filings in the most recent year tracked, matching the field-wide cooling rather than a company-specific retreat.
Reprogenesis Inc.
Named in two of the corpus's strongest co-assignee pairings, both with individual inventors rather than corporate partners — a pattern suggesting IP built around specific research relationships rather than institutional partnerships.
University of Porto + TU Ilmenau
The single strongest co-assignee pairing in the dataset, at 5 shared records — an academic collaboration that outweighs any corporate partnership tracked here.
| Assignee | Recent year | YoY |
|---|---|---|
| University of Pittsburgh – Of the Commonwealth System of Higher Education | 0 | — |
| Genzyme Holdings | 0 | — |
| REPROGENESIS INC | 0 | — |
| Alevio Therapeutics, Inc. | 0 | — |
| Asia University Industry-Academic Cooperation Foundation | 0 | — |
| Kerus Corporation | 0 | — |
| University of Porto | 0 | — |
| Taipei Medical University | 0 | — |
Where to take this analysis
The trend and assignee data point to specific next steps depending on what you're evaluating.
Check freedom-to-operate against the citation leaders
Before drafting claims on injectable delivery mechanics, run a focused clearance check against the highest-cited records in this corpus — they represent the prior art most likely to be raised in examination.
Explore prior art in EurekaModel the white space in structural and genetic-engineering classes
A61F and C12N are the thinnest-claimed IPC classes here. If your work touches load-bearing scaffolds or engineered-cell co-encapsulation, that thinness is worth verifying against the full claim text, not just the class counts.
Run a white space analysis in EurekaCommon questions on hydrogel tissue-engineering patents
Filing peaked at 16 families in 2017 and has not returned to that level since, with the 2022 midpoint sitting at 9. This pattern is more consistent with a maturing claim landscape settling around established formulations than a field still expanding into new territory. It's also worth remembering that publication lags filing by roughly 18 months, so the very last year or two in any dataset will look artificially low until those applications clear examination and publish — the decline predates that lag effect, though, since it's visible well before the most recent years.
The dataset is concentrated in A61L (sterilising and disinfecting) and A61K (medicinal preparations), which together account for the large majority of records. Smaller but meaningful clusters sit in A61P (therapeutic activity), C08F, C08L and C08J (polymer chemistry and processing), and the thinnest classes are A61F (implants and prostheses) and C12N (microorganisms and genetic engineering) at just 7 records each. That distribution shows most claim activity treats the hydrogel as a drug-delivery or sterilisation vehicle rather than a structural implant or a genetically engineered therapy.
US6129761A, 'Injectable hydrogel compositions,' is cited over 1,030 times in this corpus — more than seven times the citation count of the next-most-cited record. Its dominance means most newer filings on injectable hydrogel mechanics are implicitly examined against it, so any new claim in that space should be drafted to visibly differentiate from its scope. Because citation counts favour older records in any searched corpus, this signals foundational influence rather than current commercial relevance.
The IPC composition points to structural and genetic-engineering integration as the thinnest-claimed areas: A61F (implants and prostheses) and C12N (microorganisms and genetic engineering) each carry only 7 records against 83 in A61L and 67 in A61K. Practically, that suggests load-bearing hydrogel-implant hybrids and engineered-cell co-encapsulation approaches are less crowded than formulation and delivery claims. Confirming this requires reading actual claim scope in those classes, not just the record counts, since a thin class can still contain a blocking patent.
The corpus includes academic and corporate assignees such as University of Pittsburgh's Federal system, Reprogenesis Inc., University of Porto and TU Ilmenau, among others, but none show filings in the most recent tracked year — consistent with the field-wide slowdown rather than any single exit. Co-filing is uncommon overall, with only 10 co-assignee pairs across the full dataset; the strongest pairing is an academic collaboration between University of Porto and TU Ilmenau at 5 shared records, ahead of any corporate partnership tracked here.
Research Biocompatible Hydrogels for Tissue Engineering in depth with Eureka
Go past this page: query the whole biocompatible hydrogels for tissue engineering corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.